ArticleDiscover oncology2025
Identification of cancer-associated fibroblast signature genes for potential biomarkers in cholangiocarcinoma: a Mendelian randomization study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCancer-associated fibroblasts (CAFs), integral components of the tumor microenvironment, substantially influence cholangiocarcinoma (CCA) progression and clinical outcomes. This study aimed to identify CAF-related genes implicated in CCA pathogenesis.
methodsDifferentially expressed genes (DEGs) between CCA and non-tumorous samples were extracted from the Gene Expression Omnibus GSE107943 dataset, then intersected with cancer-associated fibroblast signature genes (CAFSGs) to derive DE-CAFSGs. Mendelian randomization (MR) analysis was subsequently conducted to determine causally linked biomarkers. The diagnostic efficacy of these biomarkers was evaluated via receiver operating characteristic (ROC) curve analysis using data from GSE107943 and the TCGA-CHOL cohort. Functional annotation of representative DE-CAFSGs was performed through single-gene gene set enrichment analysis. The expression trends of these biomarkers were preliminarily explored using RT-PCR, Western blotting, and immunohistochemistry.
resultsA total of 135 DE-CAFSGs were identified, among which GRN, PLXNC1, and ORMDL3 emerged as CCA-associated biomarkers. GRN and PLXNC1 were identified as risk-associated, while ORMDL3 exhibited a protective association. Each demonstrated robust discriminatory capacity, with area under the ROC curve values exceeding 0.8 in both datasets. Enrichment analysis revealed significant associations with pathways including retinol metabolism, cytochrome P450-mediated drug metabolism, and the complement and coagulation cascades.
conclusionGRN, PLXNC1, and ORMDL3 represent key CAF-associated genes in CCA, shedding light on potential molecular mechanisms of disease development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.